Kalyoncu, E.Olmez, T. T.Ozkan, A. D.Sarioglu, O. F.2018-04-122018-04-1220161381-6128http://hdl.handle.net/11693/36631Certain bacteria selectively attack tumor tissues and trigger tumor shrinkage by producing toxins and modulating the local immune system, but their clinical utility is limited because of the dangers posed by systemic infection. Genetic engineering can be used to minimize the risks associated with tumor-targeting pathogens, as well as to increase their efficiency in killing tumor cells. Advances in genetic circuit design have led to the development of bacterial strains with enhanced tumor-targeting capacities and the ability to secrete therapeutics, cytotoxic proteins and prodrug-cleaving enzymes, which allows their safe and effective use for cancer treatment. The present review details the recent advances in the design and application of these modified bacterial strains.EnglishBifidobacteriumCancer therapyClostridiumLive vaccinesProdrug cleavageSalmonellaSynthetic biologyAntineoplastic agentCytotoxic factorDrug carrierFlucytosineFluorouracilGanciclovirLive vaccineProbiotic agentTretazicarUnclassified drugVnp 20009Antibiotic therapyAntineoplastic activityArticleBacterial membraneBacterial strainBifidobacteriumCancer diagnosisCancer recurrenceCancer therapyCD8+ T lymphocyteCell infiltrationClostridiumColony forming unitDrug activationDrug delivery systemEscherichiaGene transferGenetic engineeringImmune responseImmunogenicityMetastasisNatural killer T cellNonhumanOxygen concentrationPhase 2 clinical trial (topic)Priority journalProkaryoteSalmonellaTarget cellTumor microenvironmentType III secretion systemAnimalBacteriumBiological therapyCytologyGeneticsHumanMetabolismMicrobiologyNeoplasmsPathophysiologyProkaryotic cellAnimalsBacteriaBiological therapyHumansNeoplasmsProkaryotic cellsArticle10.2174/13816128226661512101237521873-4286